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Abstract
Aims/hypothesis Renal fibrosis is a common complication of
diabetic nephropathy and is a major cause of end-stage renal
disease. Despite the suggested link between renal fibrosis and
microRNA (miRNA) dysregulation in diabetic nephropathy,
the identification of the specific miRNAs involved is still in-
complete. The aim of this study was to investigate miRNA
profiles in the diabetic kidney and to identify potential down-
stream targets implicated in renal fibrosis.
Methods miRNA expression profiling was investigated in the
kidneys of 8-month-old Zucker diabetic fatty (ZDF) rats during
overt nephropathy. Localisation of the most upregulated miRNA
was established by in situ hybridisation. The candidate miRNA
target was identified by in silico analysis and its expression doc-
umented in the diabetic kidney associated with fibrotic markers.
Cultured tubule cells served to assess which of the profibrogenic
stimuli acted as a trigger for the overexpressed miRNA, and to
investigate underlying epigenetic mechanisms.
Results In ZDF rats, miR-184 showed the strongest differential
upregulation compared with lean rats (18-fold). Tubular
localisation of miR-184 was associated with reduced expres-
sion of lipid phosphate phosphatase 3 (LPP3) and collagen
accumulation. Transfection of NRK-52E cells with miR-184
mimic reduced LPP3, promoting a profibrotic phenotype.
Albumin was a major trigger of miR-184 expression. Anti-
miR-184 counteracted albumin-induced LPP3 downregulation
and overexpression of plasminogen activator inhibitor-1. In
ZDF rats, ACE-inhibitor treatment limited albuminuria and
reduced miR-184, with tubular LPP3 preservation and
tubulointerstitial fibrosis amelioration. Albumin-induced miR-
184 expression in tubule cells was epigenetically regulated
through DNA demethylation and histone lysine acetylation
and was accompanied by binding of NF-κB p65 subunit to
miR-184 promoter.
Conclusions/interpretation These results suggest that miR-184
may act as a downstream effector of albuminuria through LPP3
to promote tubulointerstitial fibrosis, and offer the rationale to
investigate whether targeting miR-184 in association with
albuminuria-lowering drugs may be a new strategy to achieve
fully anti-fibrotic effects in diabetic nephropathy.
Keywords Albuminuria . Diabetic nephropathy . Fibrosis .
miR-184 . Zucker diabetic fatty rats
Abbreviations
α-SMA Alpha-smooth muscle actin
ChIP Chromatin immunoprecipitation
CTGF Connective tissue growth factor
ECM Extracellular matrix
ESRD End-stage renal disease
Cristina Zanchi and Daniela Macconi contributed equally to this work.
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-017-4248-9) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
* Carlamaria Zoja
carlamaria.zoja@marionegri.it
1 IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Centro
Anna Maria Astori, Science and Technology Park Kilometro Rosso,
Via Stezzano 87, 24126 Bergamo, Italy
2 Medical University Innsbruck, Department of Internal Medicine IV–
Nephrology and Hypertension, Innsbruck, Austria
3 Biogazelle, Zwijnaarde, Belgium
4 Unit of Nephrology and Dialysis, Azienda Socio Sanitaria
Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy
5 Department of Biomedical and Clinical Sciences, University of
Milan, Milan, Italy
Diabetologia (2017) 60:1114–1125
DOI 10.1007/s00125-017-4248-9
FA Fatty acids
H3K4me3 Trimethylated histone H3 lysine 4
H3K9ac Acetylated histone H3 lysine 9
LPA Lysophosphatidate
LPP3 Lipid phosphate phosphatase 3
MBD1 Methyl-binding domain 1
MCP-1 Monocyte chemoattractant protein-1
MeCP2 Methylcytosine-binding protein 2
miRNA MicroRNA
PAI-1 Plasminogen activator inhibitor-1
qPCR Quantitative PCR
qRT-PCR Quantitative RT-PCR
TCF T cell factor
UTR Untranslated region
ZDF rats Zucker diabetic fatty rats
Introduction
Diabetic nephropathy is one of the major microvascular com-
plications of diabetes and the leading cause of chronic kidney
disease and end-stage renal disease (ESRD) throughout the
world [1, 2]. A typical hallmark of diabetic nephropathy is
excessive deposition of extracellular matrix (ECM) proteins
in the mesangium and tubulointerstitium, culminating in
glomerulosclerosis, interstitial fibrosis, tubular atrophy and
loss of renal function [3–5]. Other key features include inter-
stitial accumulation of inflammatory leucocytes and matrix-
producing myofibroblasts [6, 7]. Fibrosis is at the core of the
high morbidity and mortality rates associated with diabetic
nephropathy but specific therapeutic options with this target
are not yet available in clinics. Studies in animal models of
diabetes have contributed to defining intracellular and molec-
ular pathways driving renal fibrosis, which include the activa-
tion of the renin–angiotensin system, protein kinase C,
TGF-β1 and monocyte chemoattractant protein-1 (MCP-1)
and the upregulation of plasminogen activator inhibitor-1
(PAI-1), connective tissue growth factor (CTGF)/CCN2, col-
lagen and cytokines [8–11]. Recent studies link fibrosis to
changes in microRNAs (miRNAs), a class of short (21–24
nucleotides) noncoding RNAs that regulate gene expression
through post-translational and epigenetic mechanisms and
thereby affect several cellular processes, from development
to disease conditions [12–14]. A number of miRNAs have
been shown to be relevant to fibrotic processes in diabetic
nephropathy, including miR-29 and miR-200 families, miR-
192 and miR-21 [14–17]. These miRNAs are regulated by
TGF-β in renal cells, and normalisation of their expression
ameliorated fibrosis in in vitro and in vivo models of diabetes,
suggesting that targeting these miRNAs could be a way to
improve diabetic nephropathy downstream of TGF-β [16].
The in vivo findings were mainly obtained in early stages of
type 1 and type 2 diabetic nephropathy [14, 16].
The objective of our study was to use a rat model of type 2
diabetes (Zucker diabetic fatty [ZDF] rats) to investigate
miRNA profiles in the kidneys [18, 19] at an advanced phase
of the disease, and to identify potential downstream targets
implicated in renal fibrosis.
Methods
Experimental animals
Fifteen male ZDF (ZDF/Gmi-fa/fa) and ten non-diabetic lean
(ZDF/Gmi-fa/+) rats were purchased from Charles River
Laboratories Italia (Calco, Italy). For the first series of exper-
iments, two groups of ZDF and lean rats (n = 5/group) at
8 months of age, after blood glucose and albuminuria mea-
surement, were euthanised through CO2 inhalation and their
kidneys were collected for morphological analyses, miRNA
profiling, in situ hybridisation and immunohistochemistry. In
a subsequent study, additional ZDF rats were randomised to
receive the ACE inhibitor ramipril (1 mg/kg in the drinking
water) or vehicle (water) (n = 5/group) from 4 to 8 months of
age. Five lean rats served as controls. When rats were killed,
albuminuria and creatinine clearance were determined and
kidneys were processed for evaluation of miR-184 and Pai-1
(also known as Serpine1) mRNA and for immunohistochem-
istry. The experimenters were not blind to the treatment, but
they were blind for measurement of experimental outcomes.
Rats were housed in a specific pathogen-free facility with
constant temperature and a 12 h light–dark cycle. All proce-
dures were carried out in compliance with national (D.L.n.26,
March 4, 2014) and international laws and policies (directive
2010/63/EU) and were approved by the Institutional Animal
Care and Use Committees of Mario Negri Institute (see ESM
Methods for further details).
MicroRNA expression profiling
The miRNA profile was generated from RNA isolated
from frozen kidneys using the TaqMan Array Rodent
miRNA cards (Life Technologies, Carlsbad, CA, USA).
See ESM Methods.
Quantitative RT-PCR
Quantitative RT (qRT)-PCR analyses of miR-184, Lpp3
(also known as Plpp3) mRNA and Pai-1 mRNA were
performed in RNA isolated from kidney tissue using
specific TaqMan assays (Life Technologies). See ESM
Methods.
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In situ hybridisation and immunohistochemistry
miR-184 hybridisation was assessed on paraffin-embedded kid-
ney sections using the double-digoxigenin-labelled LNA
miRCURY probe (Exiqon, Vedbaek, Denmark). Staining for
tubule markers (aquaporin1 and Tamm–Horsfall protein), lipid
phosphate phosphatase 3 (LPP3) and type III collagen was per-
formed on kidney serial sections by immunoperoxidase using
the following rabbit primary antibodies: anti-aquaporin1 (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Tamm–
Horsfall protein (1:100; Santa Cruz Biotechnology), anti-LPP3
(1:200; Biorbyt, Cambridge, UK), anti-type III collagen (1:100;
Chemicon, Temecula, CA, USA). Double labelling for LPP3
and α-smooth muscle actin (α-SMA) was assessed by immu-
nofluorescence using rabbit anti-LPP3 antibody (1:100;
Biorbyt) and Cy3-conjugated mouse anti-α-SMA antibody
(1:200; Sigma-Aldrich, St. Louis, MO, USA) (see ESM
Methods for further details).
Bioinformatic analysis of miR-184 target genes
The microRNA body map web tool (www.mirnabodymap.
org/), the miRanda-mirSVR (http://microRNA.org/) and the
EIMMo miRNA target prediction software (http://mirz.
unibas.ch/EIMMo3/) were used to identify potential targets
of miR-184. Details are provided in ESM Methods.
In vitro studies
Luciferase assayHuman AD-293 cells (Agilent, Santa Clara,
CA, USA; negative for mycoplasma contamination) were co-
transfected with a construct containing the human LPP3–3′
untranslated region (UTR) downstream of the Firefly lucifer-
ase gene, the co-reporter vector pRL-TK encoding the Renilla
luciferase and rat miR-184 mimic or control mimic using
Lipofectamine 2000 (Life Technologies). After 48 h, reporter
activity was measured with the Dual-Luciferase Reporter
(DLR) Assay System (Promega, Madison, WI, USA) (see
ESM Methods for further details).
Cell transfection and incubation Rat proximal tubule
NRK-52E cells (DSMZ, Braunschweig, Germany, negative
for mycoplasma contamination) [20] were transfected with
miR-184 mimic or control mimic using Lipofectamine 2000.
Cells were collected 24 and 48 h later for analyses of Lpp3,
Ctgf/Ccn2, Pai-1, Tgf-β (also known as Tgfb1) and Mcp-1
(Ccl2) mRNA expression, and 72 h later for western blot of
LPP3. In selected experiments transfected cells were exposed
to ICG-001 (Selleckchem, Munich, Germany), an inhibitor of
T cell factor (TCF)/β-catenin transcription, for Pai-1 mRNA
analysis. To identify triggers of miR-184 expression,
NRK-52E cells were exposed to angiotensin II, human serum
albumin, holo-transferrin, TGF-β1 or fatty acid (FA)-free
albumin (Sigma-Aldrich). NRK-52E cells were transfected
with anti-miR-184 or miRNA inhibitor negative control be-
fore albumin stimulation for Lpp3 and Pai-1 mRNA evalua-
tion. Epigenetic regulation of miR-184 was assessed in
NRK-52E cells exposed to the chromatin-modifying drugs
5-aza-2′-deoxycytidine and 4-phenylbutyric acid for
qRT-PCR of miR-184. Further, chromatin immunoprecipita-
tion followed by quantitative (q)PCR was performed in
albumin-treated NRK-52E cells. See ESM Methods.
qRT-PCR RNAwas isolated from NRK-52E cells for analy-
sis of miR-184 expression and Lpp3 and Pai-1 mRNA using
specific TaqMan assays. Ctgf/Ccn2, Tgf-β andMcp-1 mRNA
were evaluated using SYBR Green and the primers listed in
ESM Table 1 (see ESM Methods for further details).
Western blot analysisNRK-52E cells were processed as pre-
viously described [20]. Immunodetection of LPP3 was per-
formed using rabbit anti-LPP3 (1:300; Biorbyt). See ESM
Methods.
Chromatin immunoprecipitation Chromatin immunopre-
cipitation (ChIP) analysis was performed in albumin-treated
NRK-52E cells using the following rabbit antibodies against:
methylcytosine-binding protein 2 (MeCP2, 5 μg; ab2828,
Abcam, Cambridge, UK), methyl-binding domain 1
(MBD1, 5 μg; sc-10751, Santa Cruz Biotechnology), acety-
lated histone H3 lysine 9 (H3K9ac, 2 μg; ab4441, Abcam),
trimethylated histone H3 lysine 4 (H3K4me3, 2 μg; ab8580,
Abcam) and NF-κB-p65 (5 μg; SC-372X, Santa Cruz
Biotechnology) followed by qPCR using primers (ESM
Table 1) in spanning genomic regions surrounding the miR-
184 gene. See ESM Methods.
Statistical analysis
Results are mean ± SEM. Data were analysed by ANOVA
followed by the Tukey–Cicchetti test for multiple compari-
sons, or by Student’s t test for unpaired data, as appropriate.
A p value <0.05 was considered statistically significant.
Differentially expressed miRNAs were identified using R
statistical software (https://cran.r-project.org/) by two non-
parametric tests: the Mann–Whitney test and Rank Products
algorithm (p < 0.05) and considering only the values with a
fold change greater than 2.
Results
miR-184 is upregulated in the kidneys of ZDF rats
Systemic and renal variables of the investigated rats are given
in Table 1, and are in line with previous studies [18, 19].
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MicroRNA expression profiling was performed in the kidneys
of ZDF and lean rats at 8 months of age. Statistical analysis
with two non-parametric tests (Mann–Whitney test and Rank
Products algorithm) identified 15 miRNAs that were differen-
tially expressed between ZDF and lean rats (ten upregulated
and five downregulated) (ESM Table 2). miR-184 showed the
strongest differential upregulation (18-fold). Data from
Multiplex PCR were validated by qRT-PCR, and confirmed
a 23-fold increase of miR-184 in ZDF rats (Fig. 1a), mainly
localised at the tubular epithelium (Fig. 1b), in proximal and
distal tubules, as revealed by aquaporin1 and Tamm–Horsfall
protein staining (Fig. 1c). No signal for miR-184 was detected
in the kidneys of lean rats (Fig. 1b). A weak expression was
found in the glomeruli of ZDF rats (ESM Fig. 1a).
LPP3 is a target of miR-184
To identify potential miR-184 target genes, miRNA target
prediction algorithmsmiRanda and EIMMowere used in con-
junction with the microRNA body map web tool. Of the
putative candidates, we focused on Lpp3 because it was the
only mRNA predicted as a target of miR-184 by all databases.
Notably, the binding site for miR-184 in the 3′ UTR of Lpp3
(Fig. 2a) is evolutionarily conserved among species. To con-
firm that LPP3 is a true miR-184 target, we performed lucif-
erase reporter assays using a plasmid carrying the full-length
3′ UTR of human LPP3 downstream of the luciferase gene.
Co-transfection of AD-293 cells with miR-184 mimic and the
reporter plasmid showed a 90% reduction in luciferase activity
compared with control mimic-transfected cells (Fig. 2b).
Reduced expression of LPP3 is associated with renal
fibrosis in ZDF rats
LPP3 is an integral membrane glycoprotein highly expressed
in the kidney [21, 22] that catalyses dephosphorylation of
lipid phosphates and is engaged in several physiological
and pathological processes including fibrosis [23–25].
Immunohistochemistry showed that LPP3 was uniformly
expressed throughout the tubule epithelium of lean rats, while
Table 1 Systemic and renal variables in ZDF and lean rats at 8 months of age
Group Body weight (g) Blood glucose (mmol/l) Albuminuria (mg/day) Glomerulosclerosis (%) Tubular damage (score)
Lean rats 446 ± 7 5.84 ± 0.17 0.57 ± 0.10 0 0
ZDF rats 416 ± 6* 28.98 ± 0.99*** 207 ± 28*** 22 ± 5** 1.12 ± 0.1***
Values are mean ± SEM
*p < 0.05, **p < 0.01 and ***p < 0.001 vs lean rats
Fig. 1 miR-184 is upregulated in
the kidneys of ZDF rats. (a) miR-
184 expression in lean (white bar)
and ZDF (black bar) rats (n = 5/
group). Data normalised to U87
small nucleolar RNA are reported
as fold change relative to lean rats.
**p < 0.01 vs lean rats. (b)
Representative images of in situ
hybridisation for miR-184 in
kidney cortex from a lean rat, a
ZDF rat and for scramble probe as
negative control. (c) Staining for
aquaporin1 (marker of proximal
tubules), miR-184 and Tamm–
Horsfall protein (marker of distal
tubules) in serial kidney sections
from a ZDF rat. Proximal (arrow
heads) and distal (arrows) tubules
positive for miR-184 are shown.
Scale bars, 50 μm
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in ZDF rats the staining was reduced and limited to focal
areas only (Fig. 3a). Serial kidney sections showed that in
ZDF rats miR-184 overexpression was associated with
reduced LPP3 and accumulation of interstitial type III colla-
gen, used as a marker for fibrosis (Fig. 3b).
In vitro miR-184 causes LPP3 downregulation
accompanied by a profibrotic phenotype of tubule
epithelial cells
We used NRK-52E, a rat proximal tubule cell line, for in vitro
mechanistic studies to establish a causal role of miR-184 on
LPP3 downregulation and renal fibrosis. Transfection of
NRK-52E cells with miR-184 mimic resulted in a significant
reduction in Lpp3 mRNA compared with control mimic-
transfected cells, indicating reduced mRNA stability after
complementation with miRNA mimic [26] (Fig. 4a).
Western blot analysis of LPP3 showed at least two immuno-
reactive bands with different mobility, ranging from 36 to
50 kDa, which may reflect oligomer formation and/or post-
translational protein modifications, such as glycosylation
(Fig. 4b) [23, 27]. Consistent with Lpp3 mRNA downregula-
tion, protein levels were almost halved in the miR-184 mimic-
transfected cells (Fig. 4b). Moreover, miR-184 mimic caused
a transient increase in Ctgf/Ccn2 mRNA and a sustained up-
regulation of Pai-1 mRNA (Fig. 4c,d), while it did not affect
Tgf-β (Fig. 4e). Increased levels of proinflammatory Mcp-1
were also observed (ESM Fig. 2). To investigate intracellular
Fig. 2 In vitro validation of Lpp3 as a target of miR-184. (a) Schematic
representation of Lpp3 3′UTR as a putative target for miR-184. The seed-
recognising site (position 1272–1278 of rat Lpp3 3′ UTR) binding to
miR-184 RNA is indicated. (b) Luciferase activity in AD-293 cells co-
transfected with the reporter plasmid containing the Lpp3 3′ UTR down-
stream of the Firefly luciferase gene, the co-reporter vector pRL-TK
encoding the Renilla luciferase and with control (white bar) or miR-184
(black bar) mimic. Firefly/Renilla luciferase activity was expressed as
arbitrary units (AU). Normalised luciferase activity of control mimic-
transfected cells was set to 1. ***p < 0.001 vs control mimic (n = 3
experiments)
Fig. 3 miR-184 upregulation is
associated with reduced LPP3 and
renal fibrosis in ZDF rats. (a)
Representative images, at low
magnification, of LPP3
expression in lean and ZDF rats.
Arrowheads indicate areas of
reduced LPP3 staining. (b) In situ
hybridisation for miR-184 and
immunostaining for LPP3 and
type III collagen in adjacent
kidney sections. Insets show high
magnification of a miR184-
positive tubule with reduced
LPP3 staining and surrounded by
interstitial type III collagen
deposition. Scale bars, 50 μm
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mechanisms that link downregulation of LPP3 with upregula-
tion of fibrotic genes we focused on β-catenin-mediated TCF
transcriptional activity, which is increased in conditions of
LPP3 deficiency [28] and acts as a driver for Pai-1 transcrip-
tion [29]. Treatment of cells overexpressing miR-184 with
ICG-001, a small-molecule inhibitor of TCF/β-catenin tran-
scription [30], prevented Pai-1 mRNA upregulation (Fig. 4f),
indicating the involvement of the β-catenin–TCF signalling
pathway in the profibrotic effect of LPP3 downregulation.
Albumin is a major regulator of miR-184 in proximal
tubule cells
Angiotensin II, albuminuria and TGF-β contribute to
tubulointerstitial injury and fibrosis in chronic renal diseases
and diabetic nephropathy [9, 10, 31]. To investigate whether
and which of these pathogenic insults could be a trigger for
miR-184 expression in renal tubule cells, NRK-52E cells were
exposed to the different stimuli for 6–48 h (Fig. 5a). Angiotensin
II did not stimulate miR-184. By contrast, albumin was a potent
inducer of miR-184, causing a 2.6-fold increase over control
cells at 24 h and a 6-fold increase at 48 h. The marked stimula-
tory effect of albumin was not shared by transferrin, another
component of proteinuria known to be toxic to proximal tubule
cells [32, 33]. A 2.6-fold increase in miR-184 was induced by
TGF-β at 48 h. The increase in miR-184 in cells exposed to
albumin was dose dependent, starting with a dose as low as
1 mg/ml (Fig. 5b). Next, we investigated whether FA bound to
albumin, rather than albumin itself, was responsible for miR-184
upregulation. Albumin and FA-free albumin (Fig. 5c) caused a
4.8- and 3.5-fold increase in miR-184 expression compared with
the control, respectively, suggesting a partial contribution of FA
to albumin-induced miR-184 upregulation. Albumin-induced
miR-184 expression translated into a 47% reduction in LPP3,
compared with control cells (Fig. 5d); a 32% reduction was
observed after FA-free albumin. To prove that decrease in
LPP3 in response to albumin was dependent on miR-184 upreg-
ulation, cells were transfected with anti-miR-184 or with
Fig. 4 miR-184 downregulates
LPP3 and promotes a profibrotic
phenotype in proximal tubule
cells. (a) Lpp3 mRNA in NRK-
52E cells, untreated (grey bars) or
transfected with control (white
bars) or miR-184 mimic (black
bars). (b) Representative western
blot and densitometric analysis of
LPP3. (c–e) Ctgf/Ccn2, Pai-1 and
Tgf-β mRNA in cells transfected
with control or miR-184 mimic.
(f) Effect of ICG-001 on Pai-1
mRNA (48 h) in cells transfected
with control or miR-184 mimic.
Results normalised to β-actin (a,
d, f) or GAPDH (c, e) are reported
as fold change relative to the
corresponding control group.
*p < 0.05 and **p < 0.01 vs
untreated cells; †p < 0.05,
††p < 0.01 and †††p < 0.001 vs
control mimic-transfected cells at
corresponding time; ‡p < 0.001 vs
miR-184 mimic-transfected cells
(n = 3 experiments)
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miRNA inhibitor negative control, before albumin incubation.
Compared with negative control treatment, anti-miR-184
prevented albumin-induced LPP3 downregulation (Fig. 6a)
and limited Pai-1 overexpression (Fig. 6b), indicating that
albumin exerted a profibrotic effect through miR-184/LPP3.
miR-184 is epigenetically regulated in proximal tubule
epithelial cells
To assess whether epigenetic mechanisms were responsible
for miR-184 upregulation, we first exposed NRK-52E cells
to the DNA-demethylating agent 5-aza-2′-deoxycytidine, the
histone deacetylase inhibitor 4-phenylbutyric acid or their
combination. Treating NRK-52E cells with 5-aza-2′-
deoxycytidine caused a non-significant increase in miR-184
expression (Fig. 7a). By contrast, 4-phenylbutyric acid signif-
icantly upregulated miR-184 expression, which was further
enhanced by the combined treatment. This suggests the syn-
ergistic effect of DNA demethylation and histone acetylation
on chromatin, switching from a silent compact state to an
active relaxed state to regulate miR-184 transcription [34,
35]. Next, through computational analysis of the rat genomic
region [36] surrounding the miR-184 gene, we identified a
putative CpG island located 731 bp upstream of the transcrip-
tion site of miR-184 (Fig. 7b), suitable for binding methyl-
CpG binding proteins, such as MeCP2 and MBD1, known to
act as transcriptional repressors [15]. Methyl-CpG binding
proteins, together with chromatin histone modifications, are
involved in the regulation of miR-184 in mouse brain cells
[37–39] and human Tcells [39]. We performed ChIP in NRK-
52E cells stimulated with or without albumin for 48 h, the time
of maximal miR-184 induction, followed by qPCR using
Fig. 5 Albumin is the primary regulator of miR-184 in proximal tubule
cells. (a) miR-184 expression in NRK-52E cells exposed to medium
(control, CTR), angiotensin II (10−7 mol/l), albumin (10 mg/ml), transfer-
rin (10 mg/ml) or TGF-β (10 ng/ml). (b) Dose-dependent effect of
albumin on miR-184 expression at 48 h. (c) miR-184 expression in cells
exposed to medium, albumin and FA-free albumin (10 mg/ml, 48 h).
Results normalised to U87 small nucleolar RNA are reported as fold
change relative to control cells. (d) Representative western blot and den-
sitometric analysis of LPP3 in cells stimulated with albumin or FA-free
albumin (72 h). Data are from three (a–c) or four (d) experiments.
*p < 0.05, **p < 0.01 and ***p < 0.001 vs control cells
Fig. 6 Blockade of miR-184 rescues LPP3 protein and downregulates
Pai-1 mRNA in albumin-treated cells. NRK-52E cells were transfected
with anti-miR-184 or miRNA inhibitor negative control (NC), followed
by albumin stimulation (10 mg/ml, 72 h). (a) Representative western blot
and densitometric analysis of LPP3. (b) Pai-1mRNA expression. Results
normalised to β-actin are reported as fold change relative to NC-
transfected cells. **p < 0.01 vs NC; †p < 0.05 v NC plus albumin
(n = 3 experiments)
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primers spanning the CpG island (regions [R]1–3), the regions
close to the miR-184 gene (R4–5), and a downstream region
(R6) (Fig. 7b). In albumin-treated cells, ChIP-qPCR using
MeCP2 antibody revealed a reduction in MeCP2 binding to
the genomic region surrounding miR-184 (R1–6), which
reached statistical significance within the CpG island (R2)
and in the region upstream of the miR-184 transcription site
(R4) (Fig. 7c). In contrast, ChIP-qPCR using MBD1 antibody
showed a steady but non-significant reduction inMBD1 bind-
ing to the analysed genomic regions (ESM Fig. 3a). In addi-
tion, we analysed two chromatin markers associated with ac-
tively transcribed genes: H3K9ac and H3K4me3. In albumin-
stimulated cells, H3K9 acetylation was enriched only in the
genomic region upstream of the miR-184 transcription site
(R4) (Fig. 7d), whereas H3K4me3 did not show significant
enrichment (ESM Fig. 3b). Starting from the evidence of the
presence of an NF-κB binding domain 958 bp upstream of the
transcriptional site of miR-184 (Fig. 7b), we performed ChIP
assay for p65, the NF-κB subunit primarily responsible for
transcriptional activation of target genes, and demonstrated
that NF-κB was recruited to the miR-184 promoter in
albumin-treated cells compared with control cells (Fig. 7e).
Limiting albuminuria with an ACE inhibitor reduces
renal fibrosis in ZDF rats associated with miR-184/LPP3
modulation
Based on the in vitro data showing the stimulating effect of
albumin on miR-184, we moved back to the animal model
and investigated whether lowering albuminuria with an ACE
inhibitor could limit miR-184 upregulation and consequent fi-
brosis. Ramipril treatment of ZDF rats with established disease
[19], decreased albuminuria by 55% (Fig. 8a) and ameliorated
renal function (ESM Table 3) compared with untreated ZDF
rats. This was accompanied by reduction in renal miR-184 and
preservation of LPP3 in the tubular epithelium (Fig. 8b,c),
along with attenuation of fibrosis, as indicated by reduced ex-
pression of α-SMA (Fig. 8d), type III collagen (Fig. 8e) and
Pai-1 mRNA (Fig. 8f).
Fig. 7 Epigenetic mechanisms involved in albumin-induced miR-184
expression in proximal tubule cells. (a) miR-184 expression in NRK-
52E cells incubated with vehicle (DMSO), 5-aza-2′-deoxycytidine (5-
Aza, 3 μmol/l), phenylbutyric acid (PBA, 3 mmol/l) or their combination.
Results normalised to U87 small nucleolar RNA are reported as fold
change relative to DMSO-treated cells. ***p < 0.001 vs DMSO (n = 3
experiments). (b) Schematic representation of genomic portion surround-
ing the miR-184 gene. NF-κB binding domain, putative CpG island and
transcription site of miR-184 are indicated. The genomic regions,
amplified by ChIP primers, are numbered and shown as rectangles. (c–
e) MeCP2 (c), H3K9ac (d) and NF-κB p65 (e) ChIP in cells without
(controls, white bars) or with albumin (10 mg/ml, 48 h, black bars).
Input DNA and immunoprecipitated DNA samples were subjected to
qPCR using primers spanning the genomic region proximal to the miR-
184 gene (R1–R6) forMeCP2 andH3K9ac ChIPs, and primers surround-
ing the NF-κB binding site (R0) for p65 ChIP. Results normalised to input
DNA are expressed as fold enrichment relative to control cells. *p < 0.05
and **p < 0.01 vs control cells (n = 3 experiments)
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Discussion
Renal fibrosis is the final common pathway of any form of
progressive kidney disease. For many years we have been ex-
ploring the molecular mechanisms underlying the development
of renal fibrosis and found that dysregulation of the miR-324-
3p/Prep complex contributed to the fibrotic process in a model
of spontaneous progressive nephropathy [20]. Moving to dia-
betic nephropathy, here we demonstrated that miR-184 was the
most upregulated miRNA in the kidneys of ZDF rats at an
advanced phase of the disease. Among mediators of fibrosis,
albumin was the most potent stimulus of miR-184, consistent
with the putative role of albuminuria in exacerbating disease
progression in diabetic nephropathy [40].
Little information is available regarding miR-184 expres-
sion in the kidney. Renal miRNA profiling of young and old
rodents revealed upregulated miR-184 in old kidneys [41, 42],
suggesting that epigenetic regulation of renal ageing likely
occurs through inhibition of miR-184 targeted genes encoding
antioxidant-, ECM-degrading- and longevity-related proteins
[41]. In 8-month-old ZDF rats, miR-184 focally localised in
areas of damaged proximal tubules. Tubulointerstitial lesions
with deposition of ECM proteins, tubular dilation and atrophy
are common findings in progressive chronic kidney diseases
and diabetic nephropathy, culminating in renal fibrosis. Here,
we suggest a link between abnormal tubular miR-184 and
tubulointerstitial fibrosis in the diabetic kidneys through inhi-
bition of the target LPP3, which plays a key role in regulating
biosynthesis of lipid phosphates involved in multiple organ
fibrosis as well as in cell signal transduction [23–25]. Loss
of LPP3 leads to changes in bioactive lipid profile, such as
enhanced levels of lysophosphatidate (LPA) [28]. Increased re-
lease of LPA and upregulation of LPA1 receptor in kidneys of
mice with unilateral ureteral obstruction is associated with de-
velopment of tubulointerstitial fibrosis [43]. In keepingwith this,
in the kidneys of ZDF rats, dysregulation of the miR-184/LPP3
Fig. 8 ACE inhibition limits
albuminuria in association with
modulation of miR-184/LPP3
and amelioration of fibrosis. (a, b)
Albuminuria (a) and renal miR-
184 expression (b) measured in
lean rats (white bars) and
untreated (black bars) or ramipril-
treated (grey bars) ZDF rats
(n = 5/group). Results normalised
to U87 small nucleolar RNA are
reported as fold change relative to
lean rats. (c, d) Representative
images of LPP3 staining (c) and
double staining for LPP3 (green)
and α-SMA (red) (d) in kidneys
from lean rats, untreated ZDF rats
and ZDF rats treated with ramipril
(an ACE inhibitor [ACEi]). Scale
bar, 50 μm. (e, f) Quantification
of interstitial type III collagen
staining (e) and renal Pai-1
mRNA expression (f) in lean rats
(white bars) and untreated (black
bars) or ramipril-treated (grey
bars) ZDF rats (n = 5/group).
Results normalised to β-actin are
reported as fold change relative to
lean rats. **p < 0.01 and
***p < 0.001 vs lean rats;
†p < 0.05 and ††p < 0.01 vs
untreated ZDF rats
1122 Diabetologia (2017) 60:1114–1125
pathway would possibly result in increased bioactive lipid phos-
phate availability, which would activate profibrotic signalling
with a consequent accumulation of ECM proteins. Using serial
kidney sections, we did document increased type III collagen
staining in areas surrounding tubules that were positive for
miR-184 and exhibited reduced LPP3 staining. These data were
corroborated by in vitro experiments demonstrating that tubule
cells showing reduced LPP3 after miR-184 overexpression
acquired a profibrotic phenotype documented by enhanced
Ctgf/Ccn2 and Pai-1 mRNAs. The increase in Ctgf/Ccn2
mRNA was transient, consistent with previous observations in
proximal tubule cells exposed to LPA [43]. Although the present
study did not prove a direct link between LPP3 downregulation
and miR-184-induced fibrosis, in vitro experiments suggested
β-catenin/TCF signalling as one of the intracellular mechanisms
through which miR-184/LPP3 dysregulation may induce
profibrotic genes. Indeed, besides its known lipid phosphatase
activity, LPP3 may regulate β-catenin activation to the extent
that loss of LPP3 resulted in a marked increase in β-catenin-
mediated TCF transcriptional activity [28]. Notably, a
TCF/LEF-binding site is present in the promoter region of
Pai-1 [29], suggesting PAI-1 as a transcriptional target of the
Wnt/β-catenin signalling, known to be involved in renal fibrosis
in diabetes [44, 45]. Our data showed that in NRK-52E cells
with reduced LPP3 after miR-184 mimic transfection, inhibition
of β-catenin–TCF signalling by ICG-001 did prevent Pai-1
mRNA upregulation.
An interesting observation is that while Pai-1 and Ctgf/
Ccn2 mRNA levels increased in miR-184-overexpressing
cells, no changes were observed in Tgf-β transcripts. On the
other hand, the finding that miR-184 was upregulated in
TGF-β1-stimulated cells suggests that this miRNA can likely
mediate the cytokine profibrotic effects but, unlike other
miRNAs [46], does not contribute to TGF-β auto-upregula-
tion, at least in proximal tubule cells.
One key finding of the present study is that albumin is a
major trigger for miR-184 in tubule cells. Albuminuria is one
of the best clinical indicators of diabetes-induced renal
damage and is a predictor of progression to ESRD [1, 47].
Albuminuria stimulates proximal tubule cells to produce in-
flammatory and fibrogenic substances capable of either
attracting mononuclear cells into the renal interstitium or
activating resident fibroblasts and epithelial mesenchymal
transition programmes, which contribute to development of
fibrosis [31, 48, 49]. Our data, showing that albumin-
induced miR-184 in cultured tubule cells was associated with
reduced LPP3 and abnormal Pai-1mRNA (both prevented by
miR-184 antagomir treatment), suggest a functional link
between miR-184 dysregulation and albumin load-induced
renal fibrosis. Unlike albumin, angiotensin II, a critical medi-
ator of proteinuria and fibrosis [10], failed to induce miR-184
expression in NRK-52E cells, known to express angiotensin II
type 1 receptors [50], indicating that angiotensin II lacks a
direct effect on miR-184. Importantly, in ZDF rats, lowering
albuminuria using an ACE inhibitor was associated with re-
duced miR-184, preservation of tubular LPP3 and ameliora-
tion of tubulointerstitial fibrosis.
Our data show that albumin has a role in the dysregulation
of epigenetic mechanisms like DNA demethylation and his-
tone lysine acetylation, which ultimately lead to miR-184
overexpression in tubule cells. We previously demonstrated
that albumin regulates the transcription of proinflammatory
and fibrogenic genes through the activation of NF-κB signal-
ling [31]. Importantly, an NF-κB binding site is present in the
promoter of miR-184. Our finding that p65 was recruited to
miR-184 promoter in albumin-stimulated tubule cells
miR-184 promoter
NF-κB 
recognition sequence
Albumin NF-κB
MeCP2 MeCP2 MeCP2 Ac
Ac
AcMeCP2 Ac
Ac
p65
NF-κB
miR-184
LPP3
FIBROSIS
DNA
β-Cat
TCF
CBP
Pai-1
Compact chromatin Open chromatin
Fig. 9 Hypothetical pathways
through which albumin overload
promotes renal fibrosis via
epigenetic regulation of miR-184.
Albumin reduces binding of
MeCP2 to miR-184 promoter and
fosters histone lysine acetylation
(Ac), favouring accessibility of
NF-κB-p65 to its recognition
sequence on the miRNA
promoter. This results in miR-184
upregulation and repression of the
downstream target LPP3, which
in turn upregulates Pai-1
transcription through the β-
catenin (β-Cat)–TCF signalling
pathway in a cAMP response-
element binding protein (CREB)
binding protein (CBP)-dependent
fashion
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indicates that the chromatin modification events observed in
response to albumin make the miR-184 promoter region more
accessible to NF-κB, thereby inducing miR-184 transcription
(Fig. 9).
In conclusion, this study provides the novel finding that
miR-184 is predominantly expressed in the renal tubules of
ZDF rats and plays a role in tubulointerstitial fibrosis through
downregulation of LPP3. Albuminuria is the main instigator
for miR-184 expression in tubule cells under the control of
epigenetic mechanisms. These data may offer a new opportu-
nity for targeting miR-184 in association with albuminuria-
lowering drugs to achieve fully protective anti-fibrotic effects
in diabetic nephropathy.
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